Minimal lactazole scaffold for in vitro thiopeptide bioengineering.

Area of Science:

• Biochemistry
• Synthetic Biology
• Natural Product Biosynthesis

Background:

• Lactazole A is a cryptic thiopeptide produced by Streptomyces lactacystinaeus.
• Its biosynthesis is encoded by a 9.8 kb gene cluster.
• Thiopeptides represent a complex class of natural products with significant therapeutic potential.

Purpose of the Study:

• To establish an in vitro biosynthesis platform for lactazole A.
• To explore the substrate tolerance and engineering potential of lactazole biosynthetic enzymes.
• To generate diverse lactazole analogs and novel hybrid thiopeptides.

Main Methods:

• Development of the FIT-Laz system, combining flexible in vitro translation (FIT) with recombinant lactazole biosynthetic enzymes.
• Systematic dissection of the lactazole biosynthetic pathway.
• Engineering of the minimal lactazole scaffold for analog generation.

Main Results:

• Successful in vitro biosynthesis of lactazole A achieved.
• Demonstrated remarkable substrate tolerance of biosynthetic enzymes.
• Developed a minimal lactazole scaffold amenable to extensive modifications.
• Generated diverse lactazole analogs with mutations, varied macrocycle sizes, and extended tail regions.
• Created hybrid thiopeptides incorporating non-proteinogenic amino acids.

Conclusions:

• The FIT-Laz system provides a powerful platform for thiopeptide biosynthesis and engineering.
• The minimal lactazole scaffold facilitates the creation of novel thiopeptide structures.
• This approach opens avenues for exploring untapped chemical space within thiopeptides.
• Potential for discovering new therapeutic agents derived from thiopeptide scaffolds.